Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8961031 | 0.90 | CTSS (0.40) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL4973488 | 0.89 | CTSS (0.45) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL8075158 | 0.83 | KDM4E (0.36) | CTSSCTSKKDM4EALDH1A1HPGD | |
| SCHEMBL9067533 | 0.82 | CTSS (0.35) | CTSSCTSK | |
| SCHEMBL29097057 | 0.81 | CTSK (0.49) | CTSSCTSK | |
| SCHEMBL29097060 | 0.81 | CTSK (0.49) | CTSSCTSK | |
| SCHEMBL4970302 | 0.81 | CTSK (0.49) | CTSSCTSK | |
| SCHEMBL29097056 | 0.81 | CTSK (0.49) | CTSSCTSK | |
| SCHEMBL8073460 | 0.80 | CA1 (0.34) | CTSSCTSKCA2 | |
| SCHEMBL1271608 | 0.78 | GAA (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489076-B1 | CYCLIC HEMIACETAL DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7202274-B2 | Cyclic hemiacetal derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20050119499-A1 | Cyclic hemiacetal derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1489076-A1 | CYCLIC HEMIACETAL DERIVATIVE AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119499-A1 | Cyclic hemiacetal derivative and use thereof | CAPN1, CAPN2, CAPNS1 | CTSS 190/4885CTSK 798/4885KDM4E 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.